apomorphine has been researched along with Mental Disorders in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (44.00) | 18.7374 |
| 1990's | 3 (12.00) | 18.2507 |
| 2000's | 3 (12.00) | 29.6817 |
| 2010's | 8 (32.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dohgu, S; Fukae, J; Kataoka, Y; Koga, M; Matsumoto, J; Nakashima, A; Takata, F; Tsuboi, Y; Yamauchi, A | 1 |
| Drapier, D; Drapier, S; Duprez, J; Houvenaghel, JF; Riou, A; Robert, GH; Sauleau, P; Vérin, M | 1 |
| Alipour Heidari, M; Dargahi, T; Faraji, A; Fraidouni, N; Haghdoost-Yazdi, H; Mahmudi, M; Piri, H | 1 |
| Chaudhuri, KR; Evans, A; Qamar, MA; Rosa-Grilo, M | 1 |
| Buitelaar, JK; Cools, L; de Jong, CA; Ellenbroek, B; Schellekens, AF; van Oosterwijck, AW; Verkes, RJ | 1 |
| Ding-Fang, C; Guo-Hua, W; Hong-Min, T; Hua-Wei, L; Jun, M; Jun-Peng, G; Shan, S; Wen-Wei, L; Xiang-Yu, W; Ya-Ling, H; Yan-Hong, T; Yi, F; Yue, F; Yun-Ke, Y | 1 |
| Belluzzi, JD; Buell, M; Chung, S; Civelli, O; Geyer, MA; Hesseling, P; Martens, GJ; van Vugt, RW; Verheij, MM | 1 |
| Cui, YQ; Jia, YJ; Wang, XM; Zhang, QB; Zhang, T | 1 |
| Carballo-Cordero, M; Giménez de Béjar, V | 1 |
| LANG, A; MESTRALLET, A | 1 |
| NAHUNEK, K | 1 |
| Borges-Gonzalez, S; Flockhart, D; Preskorn, SH | 1 |
| Martens, GJ; van Loo, KM | 1 |
| Meltzer, HY | 1 |
| Sternberg, DE | 1 |
| Bench, CJ; Cowen, PJ; Dolan, RJ; Frackowiak, RS; Friston, KJ; Frith, CD; Grasby, PM; Liddle, PF | 1 |
| Bailey, PE; Crocq, MA; Duval, F; Macher, JP; Mokrani, MC | 1 |
| Marsden, CD; Nordera, G; Stocchi, F | 1 |
| Bunney, WE | 1 |
| Horowski, R; Marsden, CD; Obeso, JA | 1 |
| Lal, S | 1 |
| Ansseau, M; Doumont, A; Geenen, V; Legros, JJ; Mantanus, H; Marissiaux, P; Timsit-Berthier, M | 1 |
| Ungerstedt, U | 1 |
| Calne, DB; Reid, JL | 1 |
8 review(s) available for apomorphine and Mental Disorders
| Article | Year |
|---|---|
The efficacy of apomorphine - A non-motor perspective.
Topics: Animals; Antiparkinson Agents; Apomorphine; Autonomic Nervous System Diseases; Disruptive, Impulse Control, and Conduct Disorders; Humans; Mental Disorders; Parkinson Disease; Sleep Wake Disorders | 2016 |
Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: Part II.
Topics: Anti-HIV Agents; Antidepressive Agents; Antiparkinson Agents; Apomorphine; Atazanavir Sulfate; Azabicyclo Compounds; Carbamates; Central Nervous System Agents; Cytochrome P-450 Enzyme System; Drug Approval; Drug Interactions; Duloxetine Hydrochloride; Furans; Humans; Hypnotics and Sedatives; Indenes; Long QT Syndrome; Mental Disorders; Oligopeptides; Organophosphates; Piperazines; Psychopharmacology; Pyridines; Sulfonamides; Thiophenes | 2006 |
Dopamine autoreceptor stimulation: clinical significance.
Topics: Apomorphine; Dopamine; Haloperidol; Humans; Huntington Disease; Mental Disorders; Neurons; Parkinson Disease; Piribedil; Receptors, Dopamine; Relaxation; Schizophrenia; Sleep; Tourette Syndrome | 1982 |
Biologic tests in psychiatry.
Topics: Anxiety Disorders; Apomorphine; Clonidine; Dexamethasone; Dextroamphetamine; Growth Hormone; Humans; Hydrocortisone; Imipramine; Lactates; Mental Disorders; Mood Disorders; Panic; Prognosis; Schizophrenia; Serotonin; Thyrotropin-Releasing Hormone | 1984 |
Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias.
Topics: Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Enzyme Inhibitors; Globus Pallidus; Humans; Levodopa; Mental Disorders; Movement Disorders; Parkinson Disease; Sleep Wake Disorders; Stereotaxic Techniques; Thalamus | 1997 |
Continuous dopaminergic stimulation: state of the art and outlook.
Topics: Antiparkinson Agents; Apomorphine; Dopamine; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Infusion Pumps; Lisuride; Mental Disorders; Movement; Neurology; Parkinson Disease; Stimulation, Chemical | 1988 |
Apomorphine in the evaluation of dopaminergic function in man.
Topics: Apomorphine; Dopamine; Humans; Mental Disorders; Nervous System Diseases | 1988 |
Antiparkinsonian drugs: pharmacological and therapeutic aspects.
Topics: Acetylcholine; Adrenergic beta-Antagonists; Amantadine; Amphetamine; Antiparkinson Agents; Apomorphine; Basal Ganglia Diseases; Carboxy-Lyases; Dihydroxyphenylalanine; Dopamine; Histamine H1 Antagonists; Humans; Mental Disorders; Methyldopa; Movement Disorders; Norepinephrine; Parasympatholytics; Serotonin; Synaptic Transmission | 1972 |
1 trial(s) available for apomorphine and Mental Disorders
| Article | Year |
|---|---|
Multihormonal responses to apomorphine in mental illness.
Topics: Adrenocorticotropic Hormone; Adult; Apomorphine; Depression; Dopamine Agonists; Female; Growth Hormone; Humans; Hydrocortisone; Injections, Subcutaneous; Male; Mental Disorders; Middle Aged; Prolactin; Receptors, Dopamine; Schizophrenia; Thyrotropin | 1995 |
16 other study(ies) available for apomorphine and Mental Disorders
| Article | Year |
|---|---|
Feeding-produced subchronic high plasma levels of uric acid improve behavioral dysfunction in 6-hydroxydopamine-induced mouse model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Apomorphine; Disease Models, Animal; Hyperuricemia; Male; Mental Disorders; Mice; Mice, Inbred ICR; Motor Activity; Oxidopamine; Oxonic Acid; Parkinson Disease, Secondary; Rotarod Performance Test; Tyrosine 3-Monooxygenase; Uric Acid | 2019 |
Effects of continuous subcutaneous apomorphine infusion in Parkinson's disease without cognitive impairment on motor, cognitive, psychiatric symptoms and quality of life.
Topics: Antiparkinson Agents; Apomorphine; Cognition; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infusions, Subcutaneous; Levodopa; Male; Mental Disorders; Middle Aged; Motor Activity; Neuropsychological Tests; Parkinson Disease; Quality of Life; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2018 |
Pretreatment with potassium channel blockers of 4-aminopyridine and tetraethylammonium attenuates behavioural symptoms of Parkinsonism induced by intrastriatal injection of 6-hydroxydopamine; the role of lipid peroxidation.
Topics: 4-Aminopyridine; Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Functional Laterality; Male; Mental Disorders; Motor Activity; Oxidopamine; Parkinsonian Disorders; Postural Balance; Potassium Channel Blockers; Rats; Rats, Wistar; Tetraethylammonium; Thiazolidinediones | 2016 |
The dopamine agonist apomorphine differentially affects cognitive performance in alcohol dependent patients and healthy controls.
Topics: Adult; Alcoholism; Apomorphine; Cognition; Diagnosis, Dual (Psychiatry); Dopamine; Dopamine Agonists; Female; Humans; Male; Mental Disorders; Middle Aged; Psychomotor Performance; Reaction Time; Receptors, Dopamine; Socioeconomic Factors | 2009 |
New evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antibodies; Antiparkinson Agents; Apomorphine; Chemokine CX3CL1; Disease Models, Animal; DNA Nucleotidylexotransferase; Dose-Response Relationship, Drug; Drug Interactions; Gene Expression Regulation; Levodopa; Male; Mental Disorders; Nerve Tissue Proteins; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reaction Time; Stereotyped Behavior; Substantia Nigra; Tyrosine 3-Monooxygenase | 2011 |
The melanin-concentrating hormone (MCH) system modulates behaviors associated with psychiatric disorders.
Topics: Animals; Apomorphine; Behavior, Animal; Dizocilpine Maleate; Hypothalamic Hormones; Injections; Male; Melanins; Mental Disorders; Mice; Mice, Inbred C57BL; Neural Inhibition; Pituitary Hormones; Rats; Reflex, Startle; Stereotyped Behavior | 2011 |
Fucoidan protects against lipopolysaccharide-induced rat neuronal damage and inhibits the production of proinflammatory mediators in primary microglia.
Topics: Analysis of Variance; Animals; Apomorphine; Brain Injuries; CD11b Antigen; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Lipopolysaccharides; Male; Mental Disorders; Microglia; Neuroprotective Agents; Polysaccharides; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Stereotyped Behavior; Tumor Necrosis Factor-alpha; Tyrosine 3-Monooxygenase | 2012 |
[Treatment of apomorphine infusion adverse effects: subcutaneous nodules and neuropsychiatric complications].
Topics: Adrenal Cortex Hormones; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Cholinesterase Inhibitors; Combined Modality Therapy; Disease Susceptibility; Dopamine Agonists; Drug Eruptions; Hallucinations; Humans; Infusions, Subcutaneous; Mental Disorders; Parkinson Disease; Physical Therapy Modalities; Psychomotor Agitation; Psychoses, Substance-Induced; Severity of Illness Index; Sleep Wake Disorders | 2012 |
[Indications, technics & results in apomorphine therapy of psychiatric alcoholism].
Topics: Alcoholism; Apomorphine; Humans; Mental Disorders; Psychoses, Alcoholic; Psychotic Disorders | 1959 |
[Treatment of manic-depressive psychoses with apomorphine].
Topics: Apomorphine; Bipolar Disorder; Humans; Mental Disorders; Morphine; Psychotic Disorders | 1950 |
Identification of genetic and epigenetic variations in a rat model for neurodevelopmental disorders.
Topics: Animals; Apomorphine; Base Sequence; Chromosome Mapping; Chromosomes, Human, Pair 9; Disease Models, Animal; DNA Primers; Gene Rearrangement; Genetic Predisposition to Disease; Genetic Variation; Humans; Membrane Proteins; Mental Disorders; Molecular Sequence Data; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Rats; Rats, Wistar; Schizophrenia | 2007 |
The effect of the dopamine agonist, apomorphine, on regional cerebral blood flow in normal volunteers.
Topics: Adult; Apomorphine; Brain; Cerebrovascular Circulation; Dopamine; Humans; Language Tests; Male; Memory; Mental Disorders; Neurotransmitter Agents; Placebos; Radiography; Regional Blood Flow; Tomography, Emission-Computed | 1993 |
Nonstriatal dopaminergic neurons: Section XI. Dopaminergic neurons and mental diseases: Introduction: dopaminergic neurons and mental diseases.
Topics: Apomorphine; Bromocriptine; Catecholamines; Depression; Dopamine; Homovanillic Acid; Humans; Levodopa; Mental Disorders; Neurons; Schizophrenia | 1977 |
CNV and dopamine receptor reactivity: correlations with the apomorphine test.
Topics: Adult; Apomorphine; Contingent Negative Variation; Electrophysiology; Female; Growth Hormone; Humans; Male; Mental Disorders; Receptors, Dopamine | 1986 |
Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system.
Topics: Animals; Apomorphine; Axons; Benzimidazoles; Body Weight; Brain; Brain Injuries; Brain Mapping; Catalepsy; Cerebral Ventricles; Dopamine; Feeding and Eating Disorders; Humans; Hypothalamus; Male; Mental Disorders; Microscopy, Fluorescence; Nerve Degeneration; Posture; Rats; Stereotaxic Techniques; Stimulation, Chemical; Substantia Nigra; Synaptic Transmission; Thirst | 1971 |
Levodopa and related drugs.
Topics: Amantadine; Apomorphine; Dihydroxyphenylalanine; Humans; Hydrazines; Hypotension; Mental Disorders; Movement Disorders; Nausea; Parasympatholytics; Parkinson Disease; Pyridoxine | 1973 |